Lack of Consensus Regarding Follow-Up After Keratinocyte Carcinoma Treatment
A systematic review of clinical practice guidelines revealed substantial variation in recommendations for follow-up after initial treatment for keratinocyte carcinoma.
A systematic review of clinical practice guidelines revealed substantial variation in recommendations for follow-up after initial treatment for keratinocyte carcinoma.
Patients with breast implants are at risk of developing squamous cell carcinoma and various types of lymphoma in the capsules around the implants.
Researchers observed robust antitumor activity and good tolerability in a phase 2 study of nivolumab for first-line treatment of advanced cutaneous squamous cell carcinoma.
Following an initial extensive review, the FDA identified less than 20 cases of SCC and less than 30 cases of various lymphomas in the capsule around the breast implant.
The skin microbiome may serve as biomarker for skin cancer progression.
Pembrolizumab plus chemotherapy did not improve overall survival in patients with a PD-L1 combined positive score below 1.
Patients in the very high risk group had a significantly higher risk of recurrence, metastasis, and death.
Researchers compared the prognosis of patients with S-ITM and those with T3N0, T4N0, N1-N3, and M1 disease.
Mohs micrographic surgery defect sizes were 17% larger among Hispanic/Latino patients.
Among patients younger than 49 years, those with actinic keratosis had a nearly 7-times greater likelihood of developing cutaneous squamous cell carcinoma than patients without actinic keratosis.